Zealand Pharma’s Lixisenatide Effective Mornings and Evenings

Zealand Pharma A/S (ZEAL) said a study has shown both morning and evening administration of its once-daily diabetes drug lixisenatide significantly cut blood sugar levels.

To contact the editor responsible for this story: Frances Schwartzkopff at fschwartzko1@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.